NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

See a complete list of all our guidance and quality standards currently open for consultation ...

Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Timings are approximate. For a full description of the appraisal process, please see our Health Technology Evaluation manual. Topics are referred to us by ministers following the topic selection ...